目的探讨人乙醛脱氢酶家族1成员A3(aldehyde dehydrogenase 1 family member A3,ALDH1A3)在胰腺癌及正常胰腺组织中的表达情况,并研究其对胰腺癌侵袭的调控及可能的机制。方法利用癌症和肿瘤基因图谱(the Cancer Genome Atlas,TCGA)数...目的探讨人乙醛脱氢酶家族1成员A3(aldehyde dehydrogenase 1 family member A3,ALDH1A3)在胰腺癌及正常胰腺组织中的表达情况,并研究其对胰腺癌侵袭的调控及可能的机制。方法利用癌症和肿瘤基因图谱(the Cancer Genome Atlas,TCGA)数据库中胰腺癌患者数据集、基因组织表达项目(Genotype-Tissue Expression Project,GTEx)中正常胰腺组织基因表达谱数据和肿瘤细胞系百科全书(Cancer Cell Line Encyclopedia,CCLE)数据库中胰腺癌细胞系的基因表达谱矩阵,分析ALDH家族各亚型的表达情况;Transwell实验检测敲低ALDH1A3对胰腺癌细胞侵袭能力的影响;基因富集分析(gene set enrichment analysis,GSEA)探讨ALDH1A3与JAK/STAT3通路活化的关系。结果 ALDH1A3在胰腺癌组织中的表达高于正常胰腺组织;在胰腺癌细胞系中的表达高于其他ALDH亚型;下调ALDH1A3可以降低胰腺癌细胞系的侵袭能力;JAK/STAT3通路在ALDH1A3高表达胰腺癌患者中显著富集;下调ALDH1A3可抑制STAT3的磷酸化。结论 ALDH1A3参与调控胰腺癌细胞的侵袭,其机制可能与JAK/STAT3通路的活化有关。展开更多
目的系统评价携带细胞色素P450家族3亚家族A成员5(CYP3A5)*1对移植患儿他克莫司给药剂量、血药浓度和血药浓度/给药剂量(C/D)值的影响。方法计算机检索PubMed、Scopus、ISI Web of Science、ProQuest、中国知网、维普资讯中文期刊服务...目的系统评价携带细胞色素P450家族3亚家族A成员5(CYP3A5)*1对移植患儿他克莫司给药剂量、血药浓度和血药浓度/给药剂量(C/D)值的影响。方法计算机检索PubMed、Scopus、ISI Web of Science、ProQuest、中国知网、维普资讯中文期刊服务平台、万方数据知识服务平台,纳入携带CYP3A5*1(CYP3A5*1/*1或CYP3A5*1/*3)对移植患儿他克莫司给药剂量、血药浓度、C/D值影响的文献。评价文献质量及提取资料后,采用RevMan 5.3软件进行Meta分析。结果共纳入13篇文献进行Meta分析。Meta分析结果显示,在移植后第1、2、3、6、12个月时,CYP3A5*1携带者和非携带者的他克莫司给药剂量差异有统计学意义(P<0.05),其中携带者的他克莫司给药剂量更大;在移植后第1、2周和第1、2、6个月,CYP3A5*1携带者的他克莫司血药浓度低于CYP3A5*1非携带者(P<0.05);在移植后第1、2周和第1、2、3、4、5、6、7、8、9、10、11、12个月,CYP3A5*1携带者的他克莫司C/D值低于CYP3A5*1非携带者(P<0.05)。结论在移植患儿中,CYP3A5*1携带者和非携带者移植后的他克莫司给药剂量、血药浓度和C/D值存在明显差异,其中CYP3A5*1携带者所需的他克莫司剂量更大。在给药前进行CYP3A基因多态性检测有助于预测个体所需剂量。展开更多
BACKGROUND Limonin is one of the most abundant active ingredients of Tetradium ruticarpum.It exerts antitumor effects on several kinds of cancer cells.However,whether limonin exerts antitumor effects on colorectal can...BACKGROUND Limonin is one of the most abundant active ingredients of Tetradium ruticarpum.It exerts antitumor effects on several kinds of cancer cells.However,whether limonin exerts antitumor effects on colorectal cancer(CRC)cells and cancer stem-like cells(CSCs),a subpopulation responsible for a poor prognosis,is unclear.AIM To evaluate the effects of limonin on CSCs derived from CRC cells.METHODS CSCs were collected by culturing CRC cells in serum-free medium.The cytotoxicity of limonin against CSCs and parental cells(PCs)was determined by cholecystokinin octapeptide-8 assay.The effects of limonin on stemness were detected by measuring stemness hallmarks and sphere formation ability.RESULTS As expected,limonin exerted inhibitory effects on CRC cell behaviors,including cell proliferation,migration,invasion,colony formation and tumor formation in soft agar.A relatively low concentration of limonin decreased the expression stemness hallmarks,including Nanog andβ-catenin,the proportion of aldehyde dehydrogenase 1-positive CSCs,and the sphere formation rate,indicating that limonin inhibits stemness without presenting cytotoxicity.Additionally,limonin treatment inhibited invasion and tumor formation in soft agar and in nude mice.Moreover,limonin treatment significantly inhibited the phosphorylation of STAT3 at Y705 but not S727 and did not affect total STAT3 expression.Inhibition of Nanog andβ-catenin expression and sphere formation by limonin was obviously reversed by pretreatment with 2μmol/L colievlin.CONCLUSION Taken together,these results indicate that limonin is a promising compound that targets CSCs and could be used to combat CRC recurrence and metastasis.展开更多
目的观察脑膜瘤患者醛脱氢酶9家族成员A1(member of the aldehyde dehydrogenase 9 family A1,ALDH9 A1)、乙醛脱氢酶2(aldehyde dehydrogenase,ALDH2)蛋白表达情况,并分析其临床意义。方法选取2015年8月-2017年5月在我院接受治疗的60...目的观察脑膜瘤患者醛脱氢酶9家族成员A1(member of the aldehyde dehydrogenase 9 family A1,ALDH9 A1)、乙醛脱氢酶2(aldehyde dehydrogenase,ALDH2)蛋白表达情况,并分析其临床意义。方法选取2015年8月-2017年5月在我院接受治疗的60例脑膜瘤患者为观察组,选取同期在我院接受治疗的脑外伤患者60例作为对照组,观察两组ALDH9 A1、ALDH2蛋白表达情况,比较两组血管内皮生长因子(VEGF-A)、基质金属蛋白酶(MMP-9)、胰岛素样生长因子-2(IGF-Ⅱ)及其受体(IGF-ⅡR)水平的差异,分析脑膜瘤患者ALDH9 A1、ALDH2蛋白表达情况与VEGF-A、MMP-9、IGF-Ⅱ和IGF-ⅡR水平的相关性。结果观察组患者的ALDH9 A1阳性和ALDH2阳性表达率均高于对照组(χ2值=70.533、86.724,P<0.001);观察组患者的VEGF-A和MMP-9蛋白表达水平均高于对照组(t=-16.866、-15.162,P<0.001);观察组患者的IGF-Ⅱ阳性和IGF-ⅡR阳性表达率均高于对照组(χ2值=101.538、112.258,P<0.001);脑膜瘤患者的ALDH9 A1、ALDH2阳性表达率与VEGF-A、MMP-9水平和IGF-Ⅱ和IGF-ⅡR阳性表达率正相关(r=0.612、0.598、0.605、0.627、0.608、0.612、0.634、0.587,P<0.05)。结论脑膜瘤患者的ALDH9 A1、ALDH2蛋白阳性表达率较高,且与EGF-A、MMP-9水平和IGF-Ⅱ和IGF-ⅡR阳性表达率明显正相关。展开更多
文摘目的探讨人乙醛脱氢酶家族1成员A3(aldehyde dehydrogenase 1 family member A3,ALDH1A3)在胰腺癌及正常胰腺组织中的表达情况,并研究其对胰腺癌侵袭的调控及可能的机制。方法利用癌症和肿瘤基因图谱(the Cancer Genome Atlas,TCGA)数据库中胰腺癌患者数据集、基因组织表达项目(Genotype-Tissue Expression Project,GTEx)中正常胰腺组织基因表达谱数据和肿瘤细胞系百科全书(Cancer Cell Line Encyclopedia,CCLE)数据库中胰腺癌细胞系的基因表达谱矩阵,分析ALDH家族各亚型的表达情况;Transwell实验检测敲低ALDH1A3对胰腺癌细胞侵袭能力的影响;基因富集分析(gene set enrichment analysis,GSEA)探讨ALDH1A3与JAK/STAT3通路活化的关系。结果 ALDH1A3在胰腺癌组织中的表达高于正常胰腺组织;在胰腺癌细胞系中的表达高于其他ALDH亚型;下调ALDH1A3可以降低胰腺癌细胞系的侵袭能力;JAK/STAT3通路在ALDH1A3高表达胰腺癌患者中显著富集;下调ALDH1A3可抑制STAT3的磷酸化。结论 ALDH1A3参与调控胰腺癌细胞的侵袭,其机制可能与JAK/STAT3通路的活化有关。
文摘目的系统评价携带细胞色素P450家族3亚家族A成员5(CYP3A5)*1对移植患儿他克莫司给药剂量、血药浓度和血药浓度/给药剂量(C/D)值的影响。方法计算机检索PubMed、Scopus、ISI Web of Science、ProQuest、中国知网、维普资讯中文期刊服务平台、万方数据知识服务平台,纳入携带CYP3A5*1(CYP3A5*1/*1或CYP3A5*1/*3)对移植患儿他克莫司给药剂量、血药浓度、C/D值影响的文献。评价文献质量及提取资料后,采用RevMan 5.3软件进行Meta分析。结果共纳入13篇文献进行Meta分析。Meta分析结果显示,在移植后第1、2、3、6、12个月时,CYP3A5*1携带者和非携带者的他克莫司给药剂量差异有统计学意义(P<0.05),其中携带者的他克莫司给药剂量更大;在移植后第1、2周和第1、2、6个月,CYP3A5*1携带者的他克莫司血药浓度低于CYP3A5*1非携带者(P<0.05);在移植后第1、2周和第1、2、3、4、5、6、7、8、9、10、11、12个月,CYP3A5*1携带者的他克莫司C/D值低于CYP3A5*1非携带者(P<0.05)。结论在移植患儿中,CYP3A5*1携带者和非携带者移植后的他克莫司给药剂量、血药浓度和C/D值存在明显差异,其中CYP3A5*1携带者所需的他克莫司剂量更大。在给药前进行CYP3A基因多态性检测有助于预测个体所需剂量。
文摘BACKGROUND Limonin is one of the most abundant active ingredients of Tetradium ruticarpum.It exerts antitumor effects on several kinds of cancer cells.However,whether limonin exerts antitumor effects on colorectal cancer(CRC)cells and cancer stem-like cells(CSCs),a subpopulation responsible for a poor prognosis,is unclear.AIM To evaluate the effects of limonin on CSCs derived from CRC cells.METHODS CSCs were collected by culturing CRC cells in serum-free medium.The cytotoxicity of limonin against CSCs and parental cells(PCs)was determined by cholecystokinin octapeptide-8 assay.The effects of limonin on stemness were detected by measuring stemness hallmarks and sphere formation ability.RESULTS As expected,limonin exerted inhibitory effects on CRC cell behaviors,including cell proliferation,migration,invasion,colony formation and tumor formation in soft agar.A relatively low concentration of limonin decreased the expression stemness hallmarks,including Nanog andβ-catenin,the proportion of aldehyde dehydrogenase 1-positive CSCs,and the sphere formation rate,indicating that limonin inhibits stemness without presenting cytotoxicity.Additionally,limonin treatment inhibited invasion and tumor formation in soft agar and in nude mice.Moreover,limonin treatment significantly inhibited the phosphorylation of STAT3 at Y705 but not S727 and did not affect total STAT3 expression.Inhibition of Nanog andβ-catenin expression and sphere formation by limonin was obviously reversed by pretreatment with 2μmol/L colievlin.CONCLUSION Taken together,these results indicate that limonin is a promising compound that targets CSCs and could be used to combat CRC recurrence and metastasis.
文摘目的观察脑膜瘤患者醛脱氢酶9家族成员A1(member of the aldehyde dehydrogenase 9 family A1,ALDH9 A1)、乙醛脱氢酶2(aldehyde dehydrogenase,ALDH2)蛋白表达情况,并分析其临床意义。方法选取2015年8月-2017年5月在我院接受治疗的60例脑膜瘤患者为观察组,选取同期在我院接受治疗的脑外伤患者60例作为对照组,观察两组ALDH9 A1、ALDH2蛋白表达情况,比较两组血管内皮生长因子(VEGF-A)、基质金属蛋白酶(MMP-9)、胰岛素样生长因子-2(IGF-Ⅱ)及其受体(IGF-ⅡR)水平的差异,分析脑膜瘤患者ALDH9 A1、ALDH2蛋白表达情况与VEGF-A、MMP-9、IGF-Ⅱ和IGF-ⅡR水平的相关性。结果观察组患者的ALDH9 A1阳性和ALDH2阳性表达率均高于对照组(χ2值=70.533、86.724,P<0.001);观察组患者的VEGF-A和MMP-9蛋白表达水平均高于对照组(t=-16.866、-15.162,P<0.001);观察组患者的IGF-Ⅱ阳性和IGF-ⅡR阳性表达率均高于对照组(χ2值=101.538、112.258,P<0.001);脑膜瘤患者的ALDH9 A1、ALDH2阳性表达率与VEGF-A、MMP-9水平和IGF-Ⅱ和IGF-ⅡR阳性表达率正相关(r=0.612、0.598、0.605、0.627、0.608、0.612、0.634、0.587,P<0.05)。结论脑膜瘤患者的ALDH9 A1、ALDH2蛋白阳性表达率较高,且与EGF-A、MMP-9水平和IGF-Ⅱ和IGF-ⅡR阳性表达率明显正相关。
